• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.细胞因子风暴与 COVID-19 的免疫调节治疗：氯喹和抗 IL-6 单克隆抗体的作用。
Int J Antimicrob Agents. 2020 Jun;55(6):105982. doi: 10.1016/j.ijantimicag.2020.105982. Epub 2020 Apr 16.
2
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.新冠病毒相关细胞因子风暴的潜在治疗方法——超越皮质类固醇
Front Immunol. 2020 Jun 16;11:1445. doi: 10.3389/fimmu.2020.01445. eCollection 2020.
3
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.抗风湿药物的抗病毒作用：COVID-19 带来的启示。
J Autoimmun. 2020 Jul;111:102468. doi: 10.1016/j.jaut.2020.102468. Epub 2020 Apr 17.
4
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴：目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
5
Thoughts on COVID-19 and autoimmune diseases.关于 COVID-19 和自身免疫性疾病的思考。
Lupus Sci Med. 2020 Apr 3;7(1):e000396. doi: 10.1136/lupus-2020-000396. eCollection 2020.
6
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.新型冠状病毒肺炎中的细胞因子风暴：现有证据与治疗策略。
Front Immunol. 2020 Jul 10;11:1708. doi: 10.3389/fimmu.2020.01708. eCollection 2020.
7
How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.新冠病毒是如何致人死亡的？不确定性正阻碍医生选择治疗方法的能力。
Nature. 2020 Apr;580(7803):311-312. doi: 10.1038/d41586-020-01056-7.
8
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?抗 SARS-CoV-2 感染的氯喹药理学视角：一种老药对抗新型冠状病毒？
Int J Antimicrob Agents. 2020 Sep;56(3):106078. doi: 10.1016/j.ijantimicag.2020.106078. Epub 2020 Jul 4.
9
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.全面更新的关于 SARS-CoV-2 和 COVID-19 的综述。
J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24.
10
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.癌症免疫治疗学会对 COVID-19 相关全身炎症反应中白细胞介素-6 信号转导的调控观点。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000930.

引用本文的文献

1
Nanoparticle approaches for manipulating cytokine delivery and neutralization.用于调控细胞因子递送与中和的纳米颗粒方法。
Front Immunol. 2025 Jun 10;16:1592795. doi: 10.3389/fimmu.2025.1592795. eCollection 2025.
2
[Multisystemic inflammatory syndrome in children with COVID-19: a rheumatology perspective].[新型冠状病毒肺炎患儿的多系统炎症综合征：风湿病学视角]
Rev Colomb Reumatol. 2021 Oct-Dec;28(4):289-299. doi: 10.1016/j.rcreu.2020.09.005. Epub 2020 Oct 17.
3
Metformin in Antiviral Therapy: Evidence and Perspectives.二甲双胍在抗病毒治疗中的应用：证据与展望
Viruses. 2024 Dec 18;16(12):1938. doi: 10.3390/v16121938.
4
Post-COVID-19: Hematological Factors Changes in Patients at Three-time Intervals.新冠病毒感染康复后：三个时间点患者血液学因素的变化
Curr Med Chem. 2025;32(18):3670-3692. doi: 10.2174/0109298673299246240625084103.
5
Pasteurella multocida activates apoptosis via the FAK-AKT-FOXO1 axis to cause pulmonary integrity loss, bacteremia, and eventually a cytokine storm.多杀巴斯德氏菌通过 FAK-AKT-FOXO1 轴激活细胞凋亡，导致肺完整性丧失、菌血症，最终引发细胞因子风暴。
Vet Res. 2024 Apr 8;55(1):46. doi: 10.1186/s13567-024-01298-7.
6
Terminalia ferdinandiana Exell. extracts reduce pro-inflammatory cytokine and PGE secretion, decrease COX-2 expression and down-regulate cytosolic NF-κB levels.Terminalia ferdinandiana Exell. 提取物可减少促炎细胞因子和 PGE 的分泌，降低 COX-2 的表达，并下调细胞质 NF-κB 水平。
Inflammopharmacology. 2024 Jun;32(3):1839-1853. doi: 10.1007/s10787-024-01462-7. Epub 2024 Apr 6.
7
A Review on Role of Inflammation in Coronavirus Disease.炎症在冠状病毒病中的作用综述
Endocr Metab Immune Disord Drug Targets. 2024;24(13):1488-1505. doi: 10.2174/0118715303265274231204075802.
8
Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study.抗白细胞介素-6药物对新冠后综合征患者样本精神病理学的影响：一项观察性研究
Brain Sci. 2024 Jan 3;14(1):47. doi: 10.3390/brainsci14010047.
9
Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases.用于治疗肺部疾病中细胞因子流入介导的炎症的纳米药物递送系统的进展。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3695-3707. doi: 10.1007/s00210-023-02882-y. Epub 2023 Dec 11.
10
Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial.BCc1 和 Hep-S 纳米螯合药物联合治疗对住院中度 COVID-19 成年患者 IL-6 的有益作用：一项随机、双盲、安慰剂对照的临床试验。
Trials. 2023 Nov 11;24(1):720. doi: 10.1186/s13063-023-07624-2.

本文引用的文献

1
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).新型冠状病毒肺炎诊疗方案（试行第七版）
Chin Med J (Engl). 2020 May 5;133(9):1087-1095. doi: 10.1097/CM9.0000000000000819.
2
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
3
Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).COVID-19 患者的皮质类固醇治疗。
Med J Aust. 2020 May;212(9):416-420. doi: 10.5694/mja2.50577. Epub 2020 Apr 8.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
7
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?氯喹抗冠状病毒的抗病毒作用的新见解：对 COVID-19 有何期待？
Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
8
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
9
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
10
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.

细胞因子风暴与 COVID-19 的免疫调节治疗：氯喹和抗 IL-6 单克隆抗体的作用。

Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.

机构信息

Department of Pharmacy, Beijing Hospital, National Centre of Gerontology, Beijing, P.R. China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.

出版信息

Int J Antimicrob Agents. 2020 Jun;55(6):105982. doi: 10.1016/j.ijantimicag.2020.105982. Epub 2020 Apr 16.

DOI:10.1016/j.ijantimicag.2020.105982
PMID:32305588
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7161506/
Abstract

• Discussion of the role of immunomodulatory agents to reduce the cytokine storm in severe cases of COVID-19. • Potential immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine, hydroxychloroquine and tocilizumab) are discussed. • Other immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19.

摘要

• 探讨免疫调节剂在降低 COVID-19 重症患者细胞因子风暴中的作用。• 讨论目前用于治疗 COVID-19 的潜在免疫调节剂（氯喹、羟氯喹和托珠单抗）。• 对于重症或危重症 COVID-19 患者，可考虑联合抗病毒药物使用其他具有良好安全性特征的免疫调节剂。